Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NextCure Inc (NXTC)
NASDAQ:NXTC
Holding NXTC?
Track your performance easily
NXTC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.00 - $2.57
Previous Close$1.08
Volume208.18K
Average Volume (3M)84.03K
Market Cap
$30.25M
Enterprise Value-$39.67M
Total Cash (Recent Filing)$75.31M
Total Debt (Recent Filing)$5.39M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Feb 27, 2025EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.09
Shares Outstanding28,006,684
10 Day Avg. Volume289,883
30 Day Avg. Volume84,027
Standard Deviation0.18
R-Squared0.04
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.35
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.70
Forecast
1Y Price Target
$3.33Price Target Upside229.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
NextCure News
PremiumCompany Announcements
NextCure Advances with New Cancer Drug Application
PremiumCompany Announcements
NextCure Reports Improved Financial Performance and Strategic Focus
PremiumCompany Announcements
NextCure to Discuss Innovative Cancer Therapies
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentNextCure is prioritizing and focusing its resources on LNCB74, a promising B7-H4 ADC in preclinical stages with an IND filing expected soon.
Innovative TechnologyThe proprietary linker technology used in LNCB74 may result in increased payload release in tumor cells and superior serum stability.
Safety ProfileLNCB74 is engineered with a 'LALA'-mutant Fc region to minimize uptake and toxicity to immune cells, enhancing its safety profile.
Bears Say
Clinical StudiesNextcure has decided to halt further enrollment for NC410's Phase Ib study in CRC and ovarian cancer in order to prioritize resources on LNCB74.
CompetitionThe B7-H4 ADC landscape is competitive with several other clinical stage players, highlighting the challenges LNCB74 may face.
Financial PerformanceAnalyst is lowering the price target to $3, given Nextcure no longer has any programs in active clinical studies.
---
Ownership Overview
―
Insiders
6.73% Mutual Funds
42.89% Other Institutional Investors
47.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $1.00 and its highest was $2.57 in the past 12 months.
What is NextCure Inc’s market cap?
Currently, no data Available
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Feb 27, 2025 which is in 68 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Nov 07, 2024. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.345 by -$0.065.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -$0.35.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 28,006,683 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.345. Following the earnings report the stock price went down -2.273%.
Which hedge fund is a major shareholder of NextCure Inc?
Among the largest hedge funds holding NextCure Inc’s share is Harbourvest Partners Llc. It holds NextCure Inc’s shares valued at 14K.
---
NextCure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.33 (229.70% Upside)
$3.33 (229.70% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 14.3%
Last 30 Days ▼ 14.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.51%
12-Months-Change
Fundamentals
Return on Equity
-57.93%
Trailing 12-Months
Asset Growth
-35.44%
Trailing 12-Months
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.
---
NXTC Stock 12 Month Forecast
Average Price Target
$3.33
▲(229.70% Upside)
Technical Analysis
Best Analysts Covering NXTC
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-27.67%
reiterated a buy rating 15 days ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -27.67% per trade.
---